• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

不同卵巢癌亚群中巨噬细胞极化的对比：一项初步研究观察。

Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study.

机构信息

ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.

Oncoinvent AS, 0484 Oslo, Norway.

出版信息

Cells. 2020 Jan 27;9(2):305. doi: 10.3390/cells9020305.

DOI:10.3390/cells9020305
PMID:32012728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7072171/
Abstract

The role of the innate immune system in ovarian cancer is gaining importance. The relevance of tumor-associated macrophages (TAM) is insufficiently understood. In this pilot project, comprising the immunofluorescent staining of 30 biopsies taken from 24 patients with ovarian cancer, we evaluated the presence of total TAM (cluster of differentiation (CD) 68 expression), M1 (major histocompatibility complex (MHC) II expression), and M2 (anti-mannose receptor C type 1 (MRC1) expression), and the blood vessel diameter. We observed a high M1/M2 ratio in low-grade ovarian cancer compared to high-grade tumors, more total TAM and M2 in metastatic biopsies, and a further increase in total TAM and M2 at interval debulking, without beneficial effects of bevacizumab. The blood vessel diameter was indicative for M2 tumor infiltration (Spearman correlation coefficient of 0.65). These data mainly reveal an immune beneficial environment in low-grade ovarian cancer in contrast to high-grade serous ovarian cancer, where immune suppression is not altered by neoadjuvant therapy.

摘要

先天免疫系统在卵巢癌中的作用正变得越来越重要。肿瘤相关巨噬细胞（TAM）的相关性尚未得到充分理解。在这个包含 24 名卵巢癌患者 30 份活检的初步研究中，我们通过免疫荧光染色评估了总 TAM（CD68 表达）、M1（主要组织相容性复合体（MHC）II 表达）和 M2（抗甘露糖受体 C 型 1（MRC1）表达）的存在情况，以及血管直径。与高级别肿瘤相比，低级别卵巢癌中观察到高 M1/M2 比值，转移性活检中总 TAM 和 M2 更多，间隔减瘤时总 TAM 和 M2 进一步增加，而贝伐单抗没有获益。血管直径提示 M2 肿瘤浸润（Spearman 相关系数为 0.65）。这些数据主要揭示了低级别卵巢癌中有利的免疫环境，而高级别浆液性卵巢癌中免疫抑制未因新辅助治疗而改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/60da826b0e6a/cells-09-00305-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/7bb60a924957/cells-09-00305-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/fd4f5964f753/cells-09-00305-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/bc123afd5d2d/cells-09-00305-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/7964db6ba4a0/cells-09-00305-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/847e91b7ad5b/cells-09-00305-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/8a1e0ebecab5/cells-09-00305-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/60da826b0e6a/cells-09-00305-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/7bb60a924957/cells-09-00305-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/fd4f5964f753/cells-09-00305-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/bc123afd5d2d/cells-09-00305-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/7964db6ba4a0/cells-09-00305-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/847e91b7ad5b/cells-09-00305-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/8a1e0ebecab5/cells-09-00305-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf6/7072171/60da826b0e6a/cells-09-00305-g007.jpg

相似文献

1
Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study.不同卵巢癌亚群中巨噬细胞极化的对比：一项初步研究观察。
Cells. 2020 Jan 27;9(2):305. doi: 10.3390/cells9020305.
2
A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.肿瘤相关巨噬细胞的高M1/M2比值与卵巢癌患者生存期延长相关。
J Ovarian Res. 2014 Feb 8;7:19. doi: 10.1186/1757-2215-7-19.
3
Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.高级别浆液性卵巢癌植入物中肿瘤相关巨噬细胞PD-L1的表达：配对原发性和转移性肿瘤的比较
Gynecol Oncol. 2017 Mar;144(3):607-612. doi: 10.1016/j.ygyno.2016.12.021. Epub 2017 Jan 5.
4
Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients.M1 极化肿瘤相关巨噬细胞在晚期卵巢癌患者预后中的作用。
Sci Rep. 2020 Apr 8;10(1):6096. doi: 10.1038/s41598-020-63276-1.
5
Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.Jagged1 通过调节乳腺癌患者肿瘤相关巨噬细胞的分化促进芳香酶抑制剂耐药性。
Breast Cancer Res Treat. 2017 Nov;166(1):95-107. doi: 10.1007/s10549-017-4394-2. Epub 2017 Jul 20.
6
Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment.卵巢低级别和高级别浆液性癌：肿瘤微环境中隐藏的不同特征
Oncotarget. 2016 Oct 18;7(42):68033-68043. doi: 10.18632/oncotarget.10797.
7
Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer.M2 极化的巨噬细胞的表达与晚期上皮性卵巢癌的不良预后相关。
Technol Cancer Res Treat. 2013 Jun;12(3):259-67. doi: 10.7785/tcrt.2012.500312. Epub 2012 Dec 26.
8
[Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma].[肿瘤相关巨噬细胞浸润在晚期上皮性卵巢癌中的预后意义]
Ai Zheng. 2009 Mar;28(3):323-7.
9
Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma.荷叶碱通过调控肿瘤相关巨噬细胞自噬和极化抑制高级别浆液性卵巢癌的血管生成作用。
Cancer Lett. 2018 Sep 28;432:144-155. doi: 10.1016/j.canlet.2018.05.049. Epub 2018 Jun 5.
10
MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer.miR-21 调节巨噬细胞的极化，增强 M2 巨噬细胞促进卵巢癌细胞化疗耐药的作用。
Life Sci. 2020 Feb 1;242:117162. doi: 10.1016/j.lfs.2019.117162. Epub 2019 Dec 16.

引用本文的文献

1
Divergent Immune-Metabolic Profiles in Endometriosis and Ovarian Cancer: A Cross-Sectional Analysis.子宫内膜异位症和卵巢癌中不同的免疫代谢特征：一项横断面分析
Cancers (Basel). 2025 Jul 12;17(14):2325. doi: 10.3390/cancers17142325.
2
Modulating ovarian cancer progression through FDX1-driven autophagy.通过FDX1驱动的自噬调节卵巢癌进展。
NPJ Precis Oncol. 2025 Jul 8;9(1):230. doi: 10.1038/s41698-025-00994-7.
3
The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials.巨噬细胞极化在卵巢癌中的作用：从分子机制到治疗潜力

本文引用的文献

1
Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.免疫抑制增加与卵巢癌腹水增加和预后不良有关。
Anticancer Res. 2019 Nov;39(11):5953-5962. doi: 10.21873/anticanres.13800.
2
Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors.初诊时髓源性抑制细胞可鉴别良恶性卵巢肿瘤。
Int J Gynecol Cancer. 2019 Nov;29(9):1381-1388. doi: 10.1136/ijgc-2019-000521.
3
Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
Front Immunol. 2025 Apr 22;16:1543096. doi: 10.3389/fimmu.2025.1543096. eCollection 2025.
4
The emerging role of glycolysis and immune evasion in ovarian cancer.糖酵解与免疫逃逸在卵巢癌中的新作用
Cancer Cell Int. 2025 Mar 5;25(1):78. doi: 10.1186/s12935-025-03698-x.
5
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond.嵌合抗原受体巨噬细胞：一种用于实体瘤及其他疾病的有前景的新型免疫疗法。
Biomark Res. 2024 Aug 23;12(1):86. doi: 10.1186/s40364-024-00637-2.
6
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.NeoPembrOv 试验的免疫组学纵向分析鉴定了高级卵巢癌免疫抵抗的驱动因素。
Nat Commun. 2024 Jul 16;15(1):5932. doi: 10.1038/s41467-024-47000-5.
7
Identification of glycosyltransferase-related genes signature and integrative analyses in patients with ovarian cancer.卵巢癌患者中糖基转移酶相关基因特征的鉴定及综合分析
Am J Clin Exp Immunol. 2024 Feb 25;13(1):12-25. doi: 10.62347/OSUA8322. eCollection 2024.
8
Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumours.新辅助化疗对妇科肿瘤免疫微环境的影响。
Ann Med. 2023;55(2):2282181. doi: 10.1080/07853890.2023.2282181. Epub 2023 Nov 20.
9
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates.用于靶向卵巢癌中髓源性抑制细胞产生的免疫抑制的药物重新利用：潜在候选药物的文献综述
Pharmaceutics. 2023 Jun 22;15(7):1792. doi: 10.3390/pharmaceutics15071792.
10
The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy.信号转导和转录激活因子在卵巢癌中的作用：探索其治疗潜力
Cancers (Basel). 2023 Apr 26;15(9):2485. doi: 10.3390/cancers15092485.
新辅助化疗在晚期上皮性卵巢癌中的作用
J Clin Oncol. 2019 Sep 20;37(27):2398-2405. doi: 10.1200/JCO.19.00022. Epub 2019 Aug 12.
4
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.髓源性抑制细胞：卵巢癌中免疫抑制的关键驱动因素。
Front Immunol. 2019 Jun 4;10:1273. doi: 10.3389/fimmu.2019.01273. eCollection 2019.
5
Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.探讨肿瘤中抗血管内皮生长因子活性的免疫机制。
Front Immunol. 2019 May 9;10:1023. doi: 10.3389/fimmu.2019.01023. eCollection 2019.
6
Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.1p36.33 缺失在低级别浆液性卵巢癌中很常见。
Neoplasia. 2019 Jun;21(6):582-590. doi: 10.1016/j.neo.2019.03.014. Epub 2019 May 1.
7
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.人类肿瘤相关巨噬细胞和单核细胞转录图谱揭示了癌症特异性重编程、生物标志物和治疗靶点。
Cancer Cell. 2019 Apr 15;35(4):588-602.e10. doi: 10.1016/j.ccell.2019.02.009. Epub 2019 Mar 28.
8
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.新辅助化疗与中间型减瘤术治疗晚期输卵管-卵巢癌：来自 EORTC 55971 和 CHORUS 试验的个体患者数据的汇总分析。
Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6.
9
Low-grade Serous Ovarian Carcinoma.低级别浆液性卵巢癌
Geburtshilfe Frauenheilkd. 2018 Oct;78(10):972-976. doi: 10.1055/a-0717-5411. Epub 2018 Oct 19.
10
Diverse Functions of Macrophages in Different Tumor Microenvironments.肿瘤微环境中巨噬细胞的多样化功能。
Cancer Res. 2018 Oct 1;78(19):5492-5503. doi: 10.1158/0008-5472.CAN-18-1367. Epub 2018 Sep 11.